TARGETING NUCLEOLAR DNA DAMAGE RESPONSE AS A NOVEL THERAPEUTIC STRATEGY FOR HIGH GRADE SEROUS OVARIAN CANCER
Grant number: 1162052 | Funding period: 2019 - 2022
Completed
Abstract
New therapies are required to improve outcomes for patients with ovarian cancer. In this proposal, we will optimise and validate the effectiveness of a new class of drugs we have discovered and developed to selectively damage the DNA of cancer cells, resulting in death of the cancers while sparing normal tissue.